Alexander Spira, MD, PhD, FACP | Authors

Alexander Spira, MD, PhD, Discusses Safety and Efficacy of Mobocertinib in EGFR ex20ins+ NSCLC Following Prior EGFR TKIs

September 14, 2021

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about clinical benefits of using mobocertinib in patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer.